Avirulent microbes and uses therefor
AssigneeWashington University
InventorRoy Gurtiss, III
Life of this patent
Estimating the term…
Abstract
This invention provides a vaccine for the immunization of a vertebrate or invertebrate comprising an avirulent derivative of a pathogenic microbe said derivative being substantially incapable of producing functional adenylate cyclase and cyclic AMP receptor protein. The invention also provides a vaccine for the immunization of a vertebrate and invertebrate comprising a virulent derivative of a pathogenic microbe said derivative being substantially incapable of producing functional adenylate cyclase and cyclic AMP receptor protein while being capable of expressing a recombinant gene derived from a pathogen of said vertebrate to produce and antigen capable of inducing an immune response in said vertebrate against said pathogen.
Claims11
A vaccine for the immunization of a vertebrate or invertebrate comprising a live avirulent bacterium selected from the group consisting of Salmonella, Escherichia and Salmonella-Escherichia hybrids obtained from a pathogenic strain of said bacterium, said pathogenic strain of said bacterium containing a gene encoding adenylate cyclase and a gene encoding cyclic AMP receptor protein and said strain of said bacterium made avirulent by an inactivating mutation in the gene encoding adenylate cyclase and an inactivating mutation in said gene encoding cyclic AMP receptor protein, and wherein upon administration with a pharmaceutically acceptable carrier to said vertebrate or invertebrate, said live avirulent bacteria is effective in evoking an immune response in said vertebrate or invertebrate to immunize against said pathogenic strain.
A vaccine for the immunization of a vertebrate or invertebrate comprising a live avirulent bacterium selected from the group consisting of Salmonella, Escherichia, and Salmonella-Escherichia hybrids obtained from a pathogenic strain of said bacterium that contains a gene encoding adenylate cyclase and a gene encoding cyclic AMP receptor protein, said pathogenic strain of said bacterium made avirulent by an inactivating mutation in the gene encoding adenylate cyclase and in the gene encoding cyclic AMP receptor protein, and wherein said strain of said bacterium also expresses a heterologous gene from a pathogenic microorganism to said vertebrate or invertebrate to produce an antigen wherein upon administration with a pharmaceutically acceptable carrier said vaccine effects an immune response in said vertebrate or invertebrate against said pathogenic microorganism.
A method for stimulating the immune system in a vertebrate or invertebrate, comprising the step of:
- administering to said vertebrate or invertebrate an amount of a live avirulent bacterium selected from the group consisting of Salmonella. Escherichia, and Salmonella-Escherichia hybrids obtained from a pathogenic strain of said bacterium, said pathogenic strain of said bacterium containing a gene encoding adenylate cyclase and a gene encoding cyclic AMP receptor protein and said strain of said bacterium made avirulent by an inactivating mutation in the gene encoding adenylate cyclase and an inactivating mutation in said gene encoding cyclic AMP receptor protein which effective in evoking an immune response in said vertebrate or invertebrate to immunize against said pathogenic strain.
A live avirulent Salmonella, Escherichia, or Salmonella-Escherichia hybrid which contains a gene encoding adenylate cyclase and a gene encoding cyclic AMP receptor protein, said Salmonella, Escherichia, or Salmonella-Escherichia hybrid made avirulent by an inactivating mutation in a gene encoding adenylate cyclase and an inactivating mutation in a gene encoding cyclic AMP receptor protein.
Dependencies are inferred from the claim text.